Phaseline

Targets › CA12

CA12 (Carbonic anhydrase 12): drug programs, companies and trials

1 program from 1 company in 20 trials: 8 Phase 1, 6 Phase 2, 5 Phase 4, 1 Phase 3; Neurology, Cardiovascular, Metabolic and endocrine; next expected readout Dec 2026.

Reversible hydration of carbon dioxide. (UniProt, O43570)

Open in Phaseline: the race on CA12, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
ShionogiAcetazolamide
Carbonic anhydrase I inhibitor; Carbonic anhydrase II inhibitor; Carbonic anhydrase XII inhibitor
CA1, CA2, CA12, CA4Phase 2Sleep Apnea; Hypobaric Hypoxia; High Altitude Effects; Post Operative Pain …Dec 2026

Conditions

Sleep Apnea (3) Obstructive Sleep Apnea (3) Hypobaric Hypoxia (1) High Altitude Effects (1) Post Operative Pain (1) Sleep Disordered Breathing (1) Acute Heart Failure (1) Type 1 Diabetes (1) Acute Decompensated Heart Failure (1) Central Sleep Apnea Comorbid With Opioid Use (1) Malignant Glioma of Brain (1) Tumor (1)

Modalities

small molecule (1)

Companies

Shionogi (1)

Related targets

CA1 (1) CA2 (1) CA4 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.